Press Releases

Financial Information

bioMérieux – Increased outlook for full-year 2021

bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2021. In light of stronger than expected respiratory panels sales in Q4, full-year 20...

Business & Solutions

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of...

Partnerships

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. T...

bioMérieux – Third-Quarter 2021 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2021.

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

On World Sepsis Day, bioMérieux, a world leader in the field of in vitro diagnostics, and the UK Sepsis Trust, an internationally renowned charity committed to help put an end to preventable deaths fr...

bioMérieux – First-Half 2021 Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 31 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statemen...